{"nctId":"NCT00417612","briefTitle":"Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets","startDateStruct":{"date":"2007-01"},"conditions":["Hypophosphatemia, Familial","Hyperparathyroidism"],"count":33,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Paricalcitol"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Paricalcitol","otherNames":["Zemplar"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of XLH rickets\n* Fasting serum calcium of 10.7 mg/dl or less\n* Fasting PTH greater than 40 nleq/ml and less than 120 nleq/ml in the mid-molecule PTH assay at screening (upper limit of normal is 25 nleq/ml)\n* Willing and able to participate in the trial\n* Taking stable dose of standard therapy for XLH rickets for at least 2 months prior to study entry\n* Concomitant therapy for XLH rickets will not be an exclusion criteria\n* Parent or guardian willing to provide informed consent, if applicable\n\nExclusion Criteria:\n\n* Concomitant kidney failure (estimated creatinine clearance less than 60 cc/min or serum creatinine greater than 1.5 mg/dl)\n* Serum 25-hydroxy vitamin D less than 20 ng/ml. Participants meeting this criterion will receive vitamin D3 supplementation for 3 months and then be rescreened.\n* Unable to comply with protocol and appropriate follow-up visits\n* Treatment with agents that may affect skeletal metabolism, such as glucocorticoids and anticonvulsants","healthyVolunteers":false,"sex":"ALL","minimumAge":"9 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement","description":"Mean area under the curve for parathyroid hormone levels (PTHauc) sampled during a 26 hour study period, for Paricalcitol (Active Drug) and Placebo groups at Baseline and Month 12 .","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1223","spread":"426"},{"groupId":"OG001","value":"1449","spread":"865"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"987","spread":"372"},{"groupId":"OG001","value":"1616","spread":"945"}]}]}]},{"type":"SECONDARY","title":"Static Parameters of Serum Alkaline Phosphatase at Baseline and 1 Year for Paricalcitol and Placebo Arms.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":"96"},{"groupId":"OG001","value":"96","spread":"28"},{"groupId":"OG002","value":"354","spread":"2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"70"},{"groupId":"OG001","value":"98","spread":"34"},{"groupId":"OG002","value":"402","spread":"211"}]}]}]},{"type":"SECONDARY","title":"Serum Calcium","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"0.5"},{"groupId":"OG001","value":"9.3","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"0.5"},{"groupId":"OG001","value":"9.3","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Bone Scan Severity Score","description":"99-Tc-methylenediphosphonate bone scans were completed and analyzed using the following scale\\*: Bone scan severity scale with minimum score of 0 and maximum score of 4 (0 is no disease and 4 is greatest severity of disease).\n\nAppearance of lumbar spine and the sacroiliac region were used as internal references to which all suspected lesions were compared, and scored as follows:\n\ngrade 0, normal scan without suspicious lesions grade 1, lesion(s) less intense than normal lumbar spine grade 2, lesion(s) similar in intensity to normal lumbar spine grade 3, lesions more intense than normal lumbar spine but similar to the normal sacroiliac region grade 4, lesions more intense than the normal sacroiliac region.\n\n\\*devised by nuclear medicine radiologist at Yale New Haven Hospital","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"1.19"},{"groupId":"OG001","value":"2.00","spread":"1.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.25"},{"groupId":"OG001","value":"2.12","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Urinary Calcium Excretion From Baseline to 1 Year","description":"Percent change in daily urinary calcium excretion, which is calculated the measurements of the calcium in the subject's 24-hr urine collections done at baseline and at the 1 year timepoints","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":"388"},{"groupId":"OG001","value":"9","spread":"36"}]}]}]},{"type":"SECONDARY","title":"Serum Intact Fibroblast Growth Factor 23 (FGF23)","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"244","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum 1,25 (OH)2D","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"18"},{"groupId":"OG001","value":"47","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":"17"},{"groupId":"OG001","value":"46","spread":"14"}]}]}]},{"type":"PRIMARY","title":"Area Under the Curve for Parathyroid Hormone (PTH; Percentage Decrease)","description":"Mean PTHauc (% decrease) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Reduction of Parathyroid Hormone Area Under the Curve (PTHauc) of 20% or Greater","description":"Clinically significant reduction of Mean PTHauc (% decrease \\>/= 20) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Elevated Serum Creatinine","Hypercalcemia"]}}}